Imexpharm Corp

Imexpharm Corp exhibits a strong liquidity position, with a current ratio of 4.05 and free cash flow of 349.97 billion VND, indicating robust short-term financial flexibility. The company's price-to-book ratio of 0.01 and price-to-tangible-book ratio of 0.01 suggest that the market is valuing the firm significantly below its book value, potentially signaling undervaluation or concerns about intangible assets. Profitability metrics are strong, with a return on equity (ROE) of 15.14% and return on assets (ROA) of 12.55%, both exceeding the typical thresholds for the pharmaceutical industry. The company's operating margin of 18.23% (calculated from operating income of 445.00 billion VND on revenue of 2.44 trillion VND) is also robust, indicating efficient cost management and pricing power. Geographically, Imexpharm is concentrated in Vietnam, with no disclosed international revenue segments. The company's business is heavily reliant on domestic demand and regulatory environments, which could expose it to local economic and policy risks. Segment-wise, the firm operates across pharmaceuticals, medical equipment, and traditional medicine, with no disclosed revenue breakdown by segment. The company's growth trajectory appears stable, with a strong free cash flow and low debt-to-equity ratio of 0.09. However, the absence of detailed revenue growth projections and the lack of international expansion plans suggest limited visibility beyond the domestic market. The company's capital expenditure of -26.88 billion VND indicates a net reduction in capital spending, which may signal a focus on cost optimization rather than expansion. Risk factors include liquidity concerns, as net cash is negative after subtracting total debt, and the potential for dilution, though currently assessed as low. The company's low price-to-earnings ratio of 0.05 and low price targets from analysts (mean of 55,333.33 VND and median of 56,000.00 VND) suggest a cautious outlook from the market. Recent events include the publication of the latest financial snapshot and analyst estimates, with no significant new filings or transcripts disclosed. The company's strategic focus on domestic operations and traditional medicine may limit its exposure to global pharmaceutical trends but also insulate it from international market volatility.